Positive effect of pentoxifylline on medication-related osteonecrosis of the jaw

被引:0
|
作者
Li, J. [1 ]
Wang, W. [1 ]
机构
[1] Kunming Med Univ, Affiliated Stomatol Hosp, Dept Oral & Maxillofacial Surg, Kunming 650106, Yunnan, Peoples R China
关键词
Pentoxifylline (PTX); Bisphosphonates(BPs); Medication-related osteonecrosis of the jaw (MRONJ); TGF-beta; 1; Phosphorous necrosis of the jaw(PNJ); BISPHOSPHONATE-RELATED OSTEONECROSIS; PHOSPHODIESTERASE INHIBITOR; BONE REPAIR; EXPRESSION; TOCOPHEROL; DIFFERENTIATION; PERSPECTIVES; ZOLEDRONATE; ALENDRONATE; MANAGEMENT;
D O I
暂无
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The pathophysiology of medication-related osteonecrosis of the jaw (MRONJ) is associated with microcirculatory dysfunction, direct toxicity to osteoblast, osteoclast and bone marrow stromal cells (BMSCs), bacterial infection, related factors, immune dysfunction, and transforming growth factor-beta (TGF-beta 1) pathway. MRONJ and osteoradionecrosis of the jaw (ORN) shared some histological characteristics, suggesting that improving blood flow, increasing blood supply to the lesion and regulating TGF-beta 1/BMP signaling can improve osteonecrosis of the jaw, thus PTX as non-selective PEDs inhibit, which can significantly improve microcirculation of ORN and anti-fibrotic drugs, have also similar preventive and therapeutic effects on MRONJ. However, as to whether PTX can treat and prevent phosphorous necrosis of the jaw(PNJ) remains to be further studied. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:264 / 267
页数:4
相关论文
共 50 条
  • [31] Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab
    Decaux, J.
    Magremanne, M.
    JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY, 2020, 121 (06) : 740 - 742
  • [32] Medication-related osteonecrosis of the jaw: Prosthodontic considerations
    Ali, Islam E.
    Sumita, Yuka
    JAPANESE DENTAL SCIENCE REVIEW, 2022, 58 : 9 - 12
  • [33] Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw
    Chopra, Kirti
    Malhan, Namrita
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E469 - E477
  • [34] Medication-related osteonecrosis of the jaw associated with aflibercept
    Zarringhalam, P.
    Brizman, E.
    Shakib, K.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2017, 55 (03): : 314 - 315
  • [35] Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw
    Metwally, Tarek
    Burke, Andrea
    Tsai, Jeffrey Y.
    Collins, Michael T.
    Boyce, Alison M.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2016, 74 (10) : 1983 - 1999
  • [36] Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw
    Lorenzo-Pouso, Alejandro I.
    Perez-Sayans, Mario
    Garcia, Abel
    Carballo, Javier
    MEDICAL HYPOTHESES, 2018, 116 : 79 - +
  • [37] Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview
    Tetradis, Sotirios
    Allen, Matthew R.
    Ruggiero, Salvatore L.
    JBMR PLUS, 2023, 7 (08)
  • [38] Position paper on medication-related osteonecrosis of the jaw (MRONJ)
    Svejda B.
    Muschitz C.
    Gruber R.
    Brandtner C.
    Svejda C.
    Gasser R.W.
    Santler G.
    Dimai H.P.
    Wiener Medizinische Wochenschrift, 2016, 166 (1-2) : 68 - 74
  • [39] Diabetes as a Risk Factor for Medication-Related Osteonecrosis of the Jaw
    Peer, A.
    Khamaisi, M.
    JOURNAL OF DENTAL RESEARCH, 2015, 94 (02) : 252 - 260
  • [40] Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)
    Ristow, Oliver
    Otto, Sven
    Troeltzsch, Matthias
    Hohlweg-Majert, Bettina
    Pautke, Christoph
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2015, 43 (02) : 290 - 293